APUS: Nilai perusahaan marang bathi resik Apimeds Pharmaceuticals US

The price trajectory of Apimeds Pharmaceuticals (APUS) helps assess the risks associated with FDA approval and the outcomes of bee venom-based drug tests, where the metric stands at -0.10. Unique patents and complex certification cycles for bioccomponents serve as a moat for the business. The company is currently relying on existing capital reserves to fund R&D developments until full-scale market sales are launched.

Apimeds Pharmaceuticals, Inc. - Pangali P/E APUS (periode 10.05.2025 - 12.11.2026)

Rincian analitis perusahaan Apimeds Pharmaceuticals

- rega lan prakiraan konsensus rega:

Rega saham Apimeds|APUS - Target konsensus

- informasi kapitalisasi pasar:

Nilai pasar Apimeds Pharmaceuticals US|APUS - Nilai Total Perusahaan

- indikator nilai aset resik miturut neraca:

Ekuitas saben Saham Apimeds Pharmaceuticals|APUS - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku apimedsus.com|APUS - Gunggung Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal Apimeds Pharmaceuticals|APUS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Apimeds|APUS - Utang perusahaan|Utang-utang marang nilai buku Apimeds Pharmaceuticals US|APUS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Apimeds Pharmaceuticals|Likuiditas darurat apimedsus.com

- rincian asil keuangan lan kelipatan valuasi:

APUS - Bathi resik|Proyeksi bathi resik Apimeds Pharmaceuticals|APUS - Koefisien rega marang bathi|Rasio prakiraan rega marang bathi Apimeds|APUS - Pangali PEG|Pangali EV/EBITDA Apimeds Pharmaceuticals US|APUS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan Apimeds Pharmaceuticals|APUS - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan apimedsus.com|APUS - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Apimeds Pharmaceuticals

Analisis komprehensif perusahaan:APUS (apimedsus.com)

The investment profile of Apimeds Pharmaceuticals (APUS) is driven by the anticipation of FDA approval for bee venom-based drugs, making current R&D expenditures the primary driver of valuation. By analyzing the issuer's P/E ratio, an investor can see the relationship between market capitalization and net income, which allows for an assessment of the cost per dollar of earnings and determines the extent of the premium paid for the company's future success in clinical trials.

Analisis perusahaan pesaing